AI Terminal
Carl Zeiss Meditec AG
Board/Management Information • Jul 27, 2016
74_rns_2016-07-27_9636362b-4696-4bbf-8ac3-2b61c03c34e1.html
Board/Management Information
Open in ViewerOpens in native device viewer
News Details
Corporate | 27 July 2016 09:00
Carl Zeiss Meditec Recruits James V. Mazzo to Lead its Newly Consolidated Ophthalmology Organization
DGAP-News: Carl Zeiss Meditec AG / Key word(s): Change of Personnel
2016-07-27 / 09:00
The issuer is solely responsible for the content of this announcement.
| Carl Zeiss Meditec Recruits James V. Mazzo to Lead its Newly Consolidated Ophthalmology Organization |
| Carl Zeiss Meditec AG consolidates its ophthalmology activities in a single Strategic Business Unit; James V. Mazzo will head the new ophthalmology division. |
Jena, Germany, July 27 th , 2016
Carl Zeiss Meditec AG has been expanding its ophthalmology business over the last years. Today, it has the broadest line of diagnostic and surgical products in the industry. Consolidating the product lines into a single Strategic Business Unit led by a proven, experienced leader will facilitate more effective customer service, more aggressive market penetration and global expansion.
James V. Mazzo will join Carl Zeiss Meditec as Global President of Ophthalmology with responsibility for the new Strategic Business Unit Ophthalmology as well as Carl Zeiss Meditec’s U.S. Sales and Service Center. Jim Mazzo is one of the industry’s best known and most respected business leaders with over 35 years of ophthalmic experience. He spent over 20 years leading Allergan’s North American and European eye care organizations. He led the public spin-off of AMO as Chairman/CEO, built that organization into a leading company in refractive, cataract and eye care products. In 2009 Abbott Labs purchased AMO and Mazzo was selected as EVP to lead Abbott’s global ophthalmology business. He left Abbott in 2013 to become executive chair and CEO of AcuFocus and Executive Chair of Neurotech.
In a joint statement by Executive and Supervisory Board of Carl Zeiss Meditec AG, Dr. Ludwin Monz, President & CEO, and Dr. Michael Kaschke, Chairman of the Supervisory Board, comment: “We are excited to have Mr. Mazzo, one of the best experts in the ophthalmology industry join the ZEISS family. The re-organization and new leadership of the ophthalmology business will allow Carl Zeiss Meditec to extend the offering for ophthalmology and optometric customers globally. We see particular opportunities in extending the business in North America and parts of Asia.”
“I am privileged and honored to be joining Carl Zeiss Meditec. The company has been an innovative leader in the industry for over 100 years. The broad line of technology and commitment to our industry is exciting. I look forward to continuing this excellence and building ZEISS into the premier ophthalmic franchise,” says James V. Mazzo.
Carl Zeiss Meditec AG is listed on TecDAX of the German stock exchange and based in Jena, Germany. In fiscal year 2014/15 it achieved revenues of 1.04 bn EUR. The ZEISS Group owns 65% of the shares and the majority of Carl Zeiss Meditec AG. The ZEISS Group reached revenues of 4.5 bn EUR in the same fiscal year.
Contact for the press
Alice Swinton
Director Global Communications, Carl Zeiss Meditec Inc.
Office: +1 925 560 5163
Contact for investors
Sebastian Frericks
Director Investor Relations Carl Zeiss Meditec AG
Phone: +49 3641 220-106
Email: [email protected]
2016-07-27 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de
| Language: | English |
| Company: | Carl Zeiss Meditec AG |
| Göschwitzer Str. 51-52 | |
| 07745 Jena | |
| Germany | |
| Phone: | +49 (0)3641 220-0 |
| Fax: | +49 (0)3641 220-112 |
| E-mail: | [email protected],[email protected] |
| Internet: | www.meditec.zeiss.de |
| ISIN: | DE0005313704 |
| WKN: | 531370 |
| Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange; Terminbörse EUREX |
| End of News | DGAP News Service |